Hookipa Biotech

<p>Hookipa Biotech AG is developing a new class of innovative immunotherapeutics and vaccines based on its proprietary Vaxwave^{<small>®</small>} technology. The Vaxwave^{<small>®</small>} technology is a novel immunotherapy platform using a <nobr>replication-defective</nobr> viral vector for the prevention and treatment of cancer and infectious diseases. The platform is one of the most promising new technologies for next generation immunotherapy & vaccines due to its ability to stimulate both potent <nobr>B-cell</nobr> and CD8+ <nobr>T-cell</nobr> immune responses. Vaxwave^{<small>®</small>} has been validated in various disease models. Unlike other vectors, Vaxwave^{<small>®</small>} based immunotherapy can be applied repeatedly to boost the immune system. The Company is developing a lead product candidate HB101, a vaccine for immunization against cytomegalovirus (CMV) and also in the process of industrializing the Vaxwave^{<small>®</small>} technology and building a robust product pipeline in the area of <nobr>immuno-oncology</nobr> and infectious diseases</p>